You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 82 No. 5, November 1960 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (42)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Corticosteroid Treatment of Pemphigus

Experience with Fifty Cases over a Period of Ten Years

SAUL L. SANDERS, M.D.; MARVIN BRODEY, M.D.; CARL T. NELSON, M.D.

Arch Dermatol. 1960;82(5):717-724.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The last decade has seen two significant advances in the diagnosis and management of pemphigus. The first was the recognition that acantholysis and the formation of intraepidermal bullae are invaluable criteria for the proper histopathological identification of patients with true pemphigus; the second was the advent of corticosteroids, which gave dermatologists, for the first time, a consistently effective means of therapy. Clinical results during the last 10 years have confirmed the observation that internally administered corticosteroids are the best agents for controlling, but not curing, pemphigus. Despite the many risks attendant upon long-term corticosteroid therapy, it remains the only really effective treatment for this disease.

Our experience with the corticosteroid treatment of pemphigus comprises 50 patients who have been observed for as long as 124 months from the onset of their disease. The purpose of this report is to describe the clinical characteristics of this group of patients in whom . . . [Full Text PDF of this Article]


Author Affiliations

New York

Department of Dermatology, Columbia University College of Physicians and Surgeons, and the Dermatology Service, The Presbyterian Hospital, New York.


Footnotes

Received for publication May 13, 1960.

The corticosteroids used in this study were supplied through the courtesy of Merck Sharp & Dohme, Division of Merck & Co., Inc., Philadelphia, Schering Corporation, Bloomfield, N.J., and the Upjohn Company, Kalamazoo, Mich.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1960 American Medical Association. All Rights Reserved.